TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) today announced operating and financial results for the three months ended March 31, 2011, and provided an update with respect to the Company’s key business initiatives. “EpiCept made substantial progress with its most important clinical projects during the first quarter of 2011,” stated Jack Talley, President and Chief Executive Officer of EpiCept. “We were delighted with the excellent clinical results for AmiKet™, formerly known as EpiCept™ NP-1, in the treatment of chemotherapy-induced neuropathy, particularly with respect to its activity in relieving the suffering of cancer patients who have undergone taxane therapy. We were also pleased to have received the support of key opinion leaders concerning the design of the Ceplene® Phase III confirmatory clinical trial.” Mr. Talley added, “With the recent submission of the application for Special Protocol Assessment with the FDA along with a strengthened cash position, we believe we are well positioned to meet our important objectives for the rest of 2011.”
